Anavex Life Sciences Corp.
AVXLHealthcare|Biotechnology|US
$1.15
+0.04 (+3.60%)
DCF Value
$1.17
Tangible Book / Share
$1.23
Cash / Share
$1.29
Financials
Financial Snapshot
Market Cap
$106.6M
Enterprise Value
-$11.7M
Revenue (TTM)
$0.00
Net Income (TTM)
-$24.0M
Cash & Investments
$118.3M
Net Cash
$118.3M
Free Cash Flow (TTM)
-$33.7M
Operating CF (TTM)
-$33.7M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$118.3M
Quarterly Burn
$8.4M
Monthly Burn
$2.8M
Est. Runway
~14.0 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $9.2M | $27.4M | $22.9M | $22.2M | $29.2M | $152.1M | $149.2M | $151.0M | $132.2M | $102.6M | $118.3M | |
| Operating Cash Flow | -$9.2M | -$9.0M | -$12.6M | -$18.5M | -$21.3M | -$30.4M | -$24.2M | -$27.8M | -$30.8M | -$39.0M | -$33.7M | |
| Free Cash Flow | -$9.2M | -$9.0M | -$12.6M | -$18.5M | -$21.3M | -$30.4M | -$24.2M | -$27.8M | -$30.8M | -$39.0M | -$33.7M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Financing Cash Flow | $3.1M | $27.3M | $8.1M | $17.8M | $28.4M | $153.2M | $21.3M | $29.7M | $12.0M | $9.4M | $46.6M |
R&D Spending
R&D (TTM)
$20.3M
R&D Intensity
—
R&D Growth vs Prior
-46.0%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $7.3M | $10.7M | $13.3M | $22.3M | $25.2M | $33.0M | $37.9M | $43.7M | $41.8M | $37.6M | $20.3M | |
| SG&A | $8.3M | $5.0M | $6.0M | $6.8M | $5.9M | $9.0M | $13.1M | $12.0M | $11.0M | $13.8M | $10.4M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D | $7.3M | $10.7M | $13.3M | $22.3M | $25.2M | $33.0M | $37.9M | $43.7M | $41.8M | $37.6M | $20.3M | |
| SG&A | $8.3M | $5.0M | $6.0M | $6.8M | $5.9M | $9.0M | $13.1M | $12.0M | $11.0M | $13.8M | $10.4M | |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 | -$31.1M | -$42.0M | -$51.0M | -$55.8M | -$52.9M | -$51.4M | -$30.6M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $964.0K | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$14.7M | -$13.4M | -$17.4M | -$26.2M | -$30.6M | -$37.6M | -$47.6M | -$47.5M | -$43.0M | -$46.4M | -$24.0M | |
| Net Income | -$14.7M | -$13.5M | -$17.5M | -$26.3M | -$26.3M | -$37.9M | -$48.0M | -$47.5M | -$43.0M | -$46.4M | -$24.0M | |
| EPS (Diluted) | -0.42 | -0.33 | -0.39 | -0.54 | -0.45 | -0.54 | -0.62 | -0.60 | -0.52 | -0.54 | -0.26 | |
| EBITDA | -$15.0M | -$15.6M | -$19.1M | -$28.9M | -$31.1M | -$37.6M | -$47.6M | -$46.5M | -$43.0M | -$46.4M | -$21.8M | |
| Shares Out. (M) | 35.15 | 40.84 | 44.66 | 48.91 | 58.19 | 69.80 | 76.91 | 79.79 | 83.47 | 85.29 | 91.45 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $9.2M | $27.4M | $22.9M | $22.2M | $29.2M | $152.1M | $149.2M | $151.0M | $132.2M | $102.6M | $118.3M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $9.4M | $27.8M | $24.3M | $25.3M | $34.5M | $161.6M | $152.7M | $154.4M | $135.6M | $103.8M | $120.1M | |
| Total Assets | $9.5M | $27.8M | $24.4M | $25.3M | $34.5M | $161.6M | $152.7M | $154.4M | $135.6M | $103.8M | $120.1M | |
| Total Current Liabilities | $3.2M | $3.6M | $3.9M | $5.0M | $7.3M | $10.8M | $10.2M | $12.5M | $15.3M | $8.9M | $7.7M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $3.2M | $3.6M | $3.9M | $5.0M | $7.3M | $10.8M | $10.2M | $12.5M | $15.3M | $8.9M | $7.7M | |
| Stockholders' Equity | $6.3M | $24.3M | $20.5M | $20.3M | $27.2M | $150.8M | $142.5M | $141.9M | $120.3M | $94.9M | $112.4M | |
| Retained Earnings | -$78.0M | -$91.5M | -$108.9M | -$133.4M | -$159.7M | -$197.6M | -$245.6M | -$293.1M | -$336.1M | -$382.4M | -$385.6M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$9.2M | -$9.0M | -$12.6M | -$18.5M | -$21.3M | -$30.4M | -$24.2M | -$27.8M | -$30.8M | -$39.0M | -$33.7M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Free Cash Flow | -$9.2M | -$9.0M | -$12.6M | -$18.5M | -$21.3M | -$30.4M | -$24.2M | -$27.8M | -$30.8M | -$39.0M | -$33.7M | |
| Investing Cash Flow | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Financing Cash Flow | $3.1M | $27.3M | $8.1M | $17.8M | $28.4M | $153.2M | $21.3M | $29.7M | $12.0M | $9.4M | $46.6M | |
| Issuance of Stock | $3.2M | $27.3M | $8.2M | $17.8M | $28.8M | $153.2M | $22.0M | $29.7M | $12.0M | $12.1M | $10.6M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | -$34.8K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $5.1M | $4.1M | $5.5M | $6.4M | $4.9M | $8.2M | $18.4M | $16.4M | $9.4M | $11.5M | -$11.9M | |
| Net Change in Cash | -$6.1M | $18.3M | -$4.5M | -$745.0K | $7.1M | $122.9M | -$3.0M | $1.9M | -$18.8M | -$29.6M | -$110.3M |
Dilution Tracker
Shares outstanding grew 46.6% over 5 years — significant dilution
Shares Outstanding
93M
5-Year Share Growth
+46.6%
Stock Issuance (TTM)
$10.6M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 35.15 | 40.84 | 44.66 | 48.91 | 58.19 | 69.80 | 76.91 | 79.79 | 83.47 | 85.29 | 91.45 | |
| Change vs Prior % | — | 16.2% | 9.3% | 9.5% | 19.0% | 19.9% | 10.2% | 3.7% | 4.6% | 2.2% | 7.2% | |
| Stock Issuance | $3.2M | $27.3M | $8.2M | $17.8M | $28.8M | $153.2M | $22.0M | $29.7M | $12.0M | $12.1M | $10.6M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $5.1M | $4.1M | $5.5M | $6.4M | $4.9M | $8.2M | $18.4M | $16.4M | $9.4M | $11.5M | -$11.9M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE % | -233.6% | -55.5% | -85.2% | -129.6% | -96.5% | -25.1% | -33.7% | -33.5% | -35.8% | -48.9% | -21.1% | |
| ROA % | -155.1% | -48.4% | -71.6% | -103.8% | -76.1% | -23.5% | -31.4% | -30.8% | -31.7% | -44.7% | -20.0% | |
| ROIC % | 0.0% | 0.0% | 0.0% | 0.0% | -82.0% | -27.8% | -1.4% | -38.4% | -44.0% | -54.2% | -27.2% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -35.1% | -21.4% | -9.4% | 5.2% | 2.8% | |
| Net Income | -21.7% | 8.7% | -29.7% | -50.7% | 0.1% | -44.2% | -26.6% | 1.0% | 9.5% | -7.8% | |
| EPS (Diluted) | 35.4% | 21.4% | -18.2% | -38.5% | 16.7% | -20.0% | -14.8% | 3.2% | 13.3% | -3.8% | |
| Operating Cash Flow | -118.5% | 2.4% | -39.5% | -47.2% | -14.9% | -42.7% | 20.2% | -14.6% | -10.9% | -26.7% | |
| Free Cash Flow | -118.5% | 2.4% | -39.5% | -47.2% | -14.9% | -42.7% | 20.2% | -14.6% | -10.9% | -26.7% | |
| R&D Expense | 219.3% | 47.1% | 25.0% | 66.8% | 13.3% | 30.7% | 15.0% | 15.3% | -4.3% | -10.1% | |
| SG&A Expense | 72.3% | -39.9% | 19.6% | 14.3% | -14.5% | 54.0% | 44.9% | -7.8% | -8.4% | 25.2% | |
| Total Assets | -38.6% | 193.1% | -12.4% | 3.9% | 36.4% | 367.9% | -5.5% | 1.1% | -12.2% | -23.4% | |
| Book Value / Share | -74.0% | 230.9% | -22.7% | -9.6% | 12.8% | 361.6% | -14.3% | -4.0% | -19.0% | -22.8% | |
| Debt | -100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Diluted Shares | 89.1% | 16.2% | 9.3% | 9.5% | 19.0% | 19.9% | 10.2% | 3.7% | 4.6% | 2.2% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B0.94
10Y Low / Med / High3.68 / 7.62 / 20.23
EV/EBITDA0.54
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$1.17
Tangible Book / Share
$1.23
Net Current Assets / Share
$1.21
Graham Net-Net
$1.22
Cash / Share
$1.29
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -8.64 | -12.55 | -6.62 | -5.85 | -10.11 | -33.24 | -16.65 | -10.92 | -10.92 | -16.48 | -4.40 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 20.23 | 6.97 | 5.62 | 7.62 | 9.72 | 8.31 | 5.57 | 3.68 | 3.94 | 8.00 | 0.94 | |
| EV/EBITDA | -7.87 | -9.10 | -4.82 | -4.58 | -7.58 | -29.25 | -13.54 | -7.98 | -7.95 | -14.16 | 0.54 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
4.35
Safe
Piotroski F-Score
1
Weak
Forward Estimates (consensus)
| Metric | FY2027 | FY2028 | FY2029 |
|---|---|---|---|
| Revenue | $1.21B | $348.6M | $713.1M |
| Net Income | -$46.9M | $193.5M | $397.4M |
| EPS | $-0.55 | $2.27 | $4.66 |
| # Analysts (EPS) | 1 | 1 | 1 |